Table 1.
Characteristics of the patients and each session of SBRT.
| N = 85 | First SBRT | Second SBRT |
|---|---|---|
| Age (years) | ||
| Median (IQR) | 64 (56–70) | 65 (57–71) |
| Sex | ||
| Male | 67 (78.8%) | |
| Female | 18 (21.2%) | |
| Etiology | ||
| Hepatitis B virus | 60 (70.6%) | |
| Hepatitis C virus | 18 (21.2%) | |
| Non-B, Non-C | 7 (8.2%) | |
| ECOG performance status | ||
| 0–1 | 82 (96.5%) | 83 (97.6%) |
| 2 | 3 (3.5%) | 2 (2.4%) |
| Previous local treatment* | ||
| No | 4 (4.7%) | 47 (55.3%) |
| Yes | 81 (95.3%) | 38 (44.7%) |
| Surgery | 13 (15.3%) | 0 (0.0%) |
| Sessions of treatment | ||
| Median (IQR) | 3 (2–6) | 2 (1–3) |
| Pre-SBRT Child–Pugh score | ||
| 5–6 | 79 (92.9%) | 73 (85.9%) |
| 7 | 2 (2.4%) | 8 (9.4%) |
| 8–9 | 4 (4.7%) | 4 (4.7%) |
| Interval (months) | ||
| Median (IQR) | 15 (7–24) | |
| Tumor size (cm) | ||
| Median (IQR) | 1.7 (1.5–2.2) | 1.7 (1.4–2.2) |
| Gross tumor volume (cm3) | ||
| Median (IQR) | 3.6 (2.0–5.9) | 2.9 (1.7–4.6) |
| Planning target volume (cm3) | ||
| Median (IQR) | 21.0 (15.6–33.2) | 20.9 (15.1–27.5) |
| Normal liver volume (cm3) | ||
| Median (IQR) | 1210 (1046–1334) | 1166 (996–1309) |
| Mean liver dose (Gy) | ||
| Median (IQR) | 5.5 (3.8–6.9) | 5.0 (3.8–6.6) |
| Dose fractionation | ||
| 36 Gy/3fx | 7 (8.2%) | 3 (3.5%) |
| 45 Gy/3fx | 60 (70.6%) | 63 (74.1%) |
| 48 Gy/4fx | 2 (2.4%) | 2 (2.4%) |
| 60 Gy/4fx | 15 (17.6%) | 12 (14.1%) |
| 60 Gy/3fx | 1 (1.2%) | 2 (2.4%) |
| Others | 0 (0.0%) | 3 (3.5%)† |
Abbreviations: SBRT, stereotactic body radiation therapy; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group.
*Local treatments include transarterial chemoembolization, radiofrequency ablation, percutaneous ethanol injection, and surgical resection. Previous local treatment in the second SBRT session is the value of the interim period between the first and second SBRT.
†Other dose fractionations include 40 Gy/4fx, 30 Gy/3fx, and 32 Gy/4fx for patients with Child–Pugh class B.